Checkpoint Capital L.P.

SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$442.3M2026 Q3
Positions8
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

Checkpoint Capital L.P. reported 8 positions worth $442.3M as of September 30, 2026 (13F filed November 13, 2026). Largest holding: ARGX (39.3%). Biggest move: add ARGX ($48.2M).

8 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 ARGXArgenx$174.0M39.34%181,500——-0.8%
▸ 2 RYTMRhythm Pharmaceuticals$115.8M26.19%1,216,574——+12.9%
▸ 3 RVMDRevolution Medicines$86.8M19.62%422,911——-18.7%
▸ 4 CYTKCytokinetics$34.1M7.71%517,278——-19.3%
▸ 5 IRONDisc Medicine$26.2M5.92%399,830——+17.0%
▸ 6 SEPNSepterna$2.5M0.57%64,000——+6.5%
▸ 7 TRVITrevi Therapeutics$2.0M0.44%137,000——-7.2%
▸ 8 OCSOculis$929.3K0.21%99,500———

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Checkpoint Capital L.P. hold as of Q3 2026?

Checkpoint Capital L.P. reported 8 positions worth $442.3M in its Q3 2026 13F filing. Largest positions: ARGX (39.3%), RYTM (26.2%), RVMD (19.6%), CYTK (7.7%) and IRON (5.9%).

What did Checkpoint Capital L.P. buy in Q3 2026?

New positions: SEPN and OCS. Added to: ARGX, IRON, RYTM, CYTK and RVMD (6 in all).

What did Checkpoint Capital L.P. sell in Q3 2026?

Checkpoint Capital L.P. reduced or sold out of no positions in Q3 2026.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.